ABBVIE INC (4AB.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:4AB - US00287Y1091 - Common Stock
191.8 EUR
+0.6 (+0.31%)
We assign a fundamental rating of 5 out of 10 to 4AB. 4AB was compared to 83 industry peers in the Biotechnology industry. 4AB has a medium profitability rating, but doesn't score so well on its financial health evaluation. 4AB has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
4AB had positive earnings in the past year.
In the past year 4AB had a positive cash flow from operations.
4AB had positive earnings in each of the past 5 years.
In the past 5 years 4AB always reported a positive cash flow from operatings.
1.2 Ratios
The Return On Assets of 4AB (1.75%) is better than 73.49% of its industry peers.
4AB has a better Return On Invested Capital (15.64%) than 91.57% of its industry peers.
4AB had an Average Return On Invested Capital over the past 3 years of 13.67%. This is in line with the industry average of 12.51%.
The 3 year average ROIC (13.67%) for 4AB is below the current ROIC(15.64%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.75% | ||
| ROE | N/A | ||
| ROIC | 15.64% |
ROA(3y)5.07%
ROA(5y)5.21%
ROE(3y)80.76%
ROE(5y)70.31%
ROIC(3y)13.67%
ROIC(5y)12.68%
1.3 Margins
The Profit Margin of 4AB (3.94%) is better than 77.11% of its industry peers.
4AB's Profit Margin has declined in the last couple of years.
The Operating Margin of 4AB (33.05%) is better than 86.75% of its industry peers.
4AB's Operating Margin has declined in the last couple of years.
Looking at the Gross Margin, with a value of 71.16%, 4AB is in the better half of the industry, outperforming 60.24% of the companies in the same industry.
4AB's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 33.05% | ||
| PM (TTM) | 3.94% | ||
| GM | 71.16% |
OM growth 3Y-5.46%
OM growth 5Y-6.52%
PM growth 3Y-28.3%
PM growth 5Y-20.42%
GM growth 3Y0.39%
GM growth 5Y-1.92%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), 4AB is creating value.
4AB has about the same amout of shares outstanding than it did 1 year ago.
4AB has more shares outstanding than it did 5 years ago.
4AB has a worse debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 2.41 indicates that 4AB is not a great score, but indicates only limited risk for bankruptcy at the moment.
The Altman-Z score of 4AB (2.41) is better than 71.08% of its industry peers.
4AB has a debt to FCF ratio of 3.49. This is a good value and a sign of high solvency as 4AB would need 3.49 years to pay back of all of its debts.
The Debt to FCF ratio of 4AB (3.49) is better than 79.52% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 3.49 | ||
| Altman-Z | 2.41 |
ROIC/WACC1.88
WACC8.32%
2.3 Liquidity
4AB has a Current Ratio of 0.72. This is a bad value and indicates that 4AB is not financially healthy enough and could expect problems in meeting its short term obligations.
4AB has a Current ratio of 0.72. This is in the lower half of the industry: 4AB underperforms 79.52% of its industry peers.
4AB has a Quick Ratio of 0.72. This is a bad value and indicates that 4AB is not financially healthy enough and could expect problems in meeting its short term obligations.
4AB has a worse Quick ratio (0.60) than 80.72% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.72 | ||
| Quick Ratio | 0.6 |
3. Growth
3.1 Past
4AB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -12.09%.
Measured over the past 5 years, 4AB shows a small growth in Earnings Per Share. The EPS has been growing by 2.51% on average per year.
Looking at the last year, 4AB shows a small growth in Revenue. The Revenue has grown by 7.40% in the last year.
Measured over the past years, 4AB shows a quite strong growth in Revenue. The Revenue has been growing by 11.11% on average per year.
EPS 1Y (TTM)-12.09%
EPS 3Y-7.24%
EPS 5Y2.51%
EPS Q2Q%-38%
Revenue 1Y (TTM)7.4%
Revenue growth 3Y0.08%
Revenue growth 5Y11.11%
Sales Q2Q%9.1%
3.2 Future
The Earnings Per Share is expected to grow by 13.69% on average over the next years. This is quite good.
Based on estimates for the next years, 4AB will show a small growth in Revenue. The Revenue will grow by 7.42% on average per year.
EPS Next Y7.28%
EPS Next 2Y19.81%
EPS Next 3Y16.75%
EPS Next 5Y13.69%
Revenue Next Year8.73%
Revenue Next 2Y9.07%
Revenue Next 3Y8.57%
Revenue Next 5Y7.42%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
4AB is valuated rather expensively with a Price/Earnings ratio of 23.62.
77.11% of the companies in the same industry are more expensive than 4AB, based on the Price/Earnings ratio.
When comparing the Price/Earnings ratio of 4AB to the average of the S&P500 Index (26.59), we can say 4AB is valued inline with the index average.
4AB is valuated correctly with a Price/Forward Earnings ratio of 15.36.
Based on the Price/Forward Earnings ratio, 4AB is valued cheaply inside the industry as 90.36% of the companies are valued more expensively.
4AB's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 23.80.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 23.62 | ||
| Fwd PE | 15.36 |
4.2 Price Multiples
75.90% of the companies in the same industry are more expensive than 4AB, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, 4AB is valued cheaply inside the industry as 83.13% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 20.04 | ||
| EV/EBITDA | 16.18 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
4AB has a very decent profitability rating, which may justify a higher PE ratio.
4AB's earnings are expected to grow with 16.75% in the coming years. This may justify a more expensive valuation.
PEG (NY)3.25
PEG (5Y)9.41
EPS Next 2Y19.81%
EPS Next 3Y16.75%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 3.03%, 4AB has a reasonable but not impressive dividend return.
Compared to an average industry Dividend Yield of 8.14, 4AB pays a better dividend. On top of this 4AB pays more dividend than 97.59% of the companies listed in the same industry.
Compared to an average S&P500 Dividend Yield of 2.31, 4AB pays a bit more dividend than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.03% |
5.2 History
On average, the dividend of 4AB grows each year by 7.72%, which is quite nice.
Dividend Growth(5Y)7.72%
Div Incr Years4
Div Non Decr Years4
5.3 Sustainability
489.69% of the earnings are spent on dividend by 4AB. This is not a sustainable payout ratio.
The dividend of 4AB is growing, but earnings are growing more, so the dividend growth is sustainable.
DP489.69%
EPS Next 2Y19.81%
EPS Next 3Y16.75%
FRA:4AB (12/10/2025, 7:00:00 PM)
191.8
+0.6 (+0.31%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners74.96%
Inst Owner ChangeN/A
Ins Owners0.05%
Ins Owner ChangeN/A
Market Cap338.98B
Revenue(TTM)59.64B
Net Income(TTM)2.35B
Analysts77.89
Price Target213.25 (11.18%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.03% |
Yearly Dividend5.36
Dividend Growth(5Y)7.72%
DP489.69%
Div Incr Years4
Div Non Decr Years4
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)1.85%
Min EPS beat(2)0.95%
Max EPS beat(2)2.75%
EPS beat(4)4
Avg EPS beat(4)1.21%
Min EPS beat(4)0.02%
Max EPS beat(4)2.75%
EPS beat(8)7
Avg EPS beat(8)0.95%
EPS beat(12)9
Avg EPS beat(12)0.65%
EPS beat(16)11
Avg EPS beat(16)0.49%
Revenue beat(2)1
Avg Revenue beat(2)-0.08%
Min Revenue beat(2)-0.79%
Max Revenue beat(2)0.63%
Revenue beat(4)2
Avg Revenue beat(4)0.22%
Min Revenue beat(4)-0.79%
Max Revenue beat(4)1.23%
Revenue beat(8)4
Avg Revenue beat(8)0.31%
Revenue beat(12)5
Avg Revenue beat(12)-0.17%
Revenue beat(16)5
Avg Revenue beat(16)-0.74%
PT rev (1m)2.13%
PT rev (3m)11.85%
EPS NQ rev (1m)-0.19%
EPS NQ rev (3m)0.63%
EPS NY rev (1m)0.91%
EPS NY rev (3m)-11.53%
Revenue NQ rev (1m)-0.06%
Revenue NQ rev (3m)0.52%
Revenue NY rev (1m)0.34%
Revenue NY rev (3m)0.46%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 23.62 | ||
| Fwd PE | 15.36 | ||
| P/S | 6.61 | ||
| P/FCF | 20.04 | ||
| P/OCF | 18.91 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 16.18 |
EPS(TTM)8.12
EY4.23%
EPS(NY)12.48
Fwd EY6.51%
FCF(TTM)9.57
FCFY4.99%
OCF(TTM)10.14
OCFY5.29%
SpS29
BVpS-1.28
TBVpS-45.02
PEG (NY)3.25
PEG (5Y)9.41
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.75% | ||
| ROE | N/A | ||
| ROCE | 20.86% | ||
| ROIC | 15.64% | ||
| ROICexc | 16.59% | ||
| ROICexgc | 572.43% | ||
| OM | 33.05% | ||
| PM (TTM) | 3.94% | ||
| GM | 71.16% | ||
| FCFM | 33% |
ROA(3y)5.07%
ROA(5y)5.21%
ROE(3y)80.76%
ROE(5y)70.31%
ROIC(3y)13.67%
ROIC(5y)12.68%
ROICexc(3y)15.06%
ROICexc(5y)13.91%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)17.54%
ROCE(5y)16.27%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y-1.81%
ROICexc growth 5Y-14.87%
OM growth 3Y-5.46%
OM growth 5Y-6.52%
PM growth 3Y-28.3%
PM growth 5Y-20.42%
GM growth 3Y0.39%
GM growth 5Y-1.92%
F-Score7
Asset Turnover0.45
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 3.49 | ||
| Debt/EBITDA | 2.39 | ||
| Cap/Depr | 14.25% | ||
| Cap/Sales | 1.97% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 74.59% | ||
| Profit Quality | 838.33% | ||
| Current Ratio | 0.72 | ||
| Quick Ratio | 0.6 | ||
| Altman-Z | 2.41 |
F-Score7
WACC8.32%
ROIC/WACC1.88
Cap/Depr(3y)9.59%
Cap/Depr(5y)10.06%
Cap/Sales(3y)1.45%
Cap/Sales(5y)1.5%
Profit Quality(3y)361.43%
Profit Quality(5y)328.91%
High Growth Momentum
Growth
EPS 1Y (TTM)-12.09%
EPS 3Y-7.24%
EPS 5Y2.51%
EPS Q2Q%-38%
EPS Next Y7.28%
EPS Next 2Y19.81%
EPS Next 3Y16.75%
EPS Next 5Y13.69%
Revenue 1Y (TTM)7.4%
Revenue growth 3Y0.08%
Revenue growth 5Y11.11%
Sales Q2Q%9.1%
Revenue Next Year8.73%
Revenue Next 2Y9.07%
Revenue Next 3Y8.57%
Revenue Next 5Y7.42%
EBIT growth 1Y27.38%
EBIT growth 3Y-5.38%
EBIT growth 5Y3.87%
EBIT Next Year9.29%
EBIT Next 3Y15.46%
EBIT Next 5Y11.36%
FCF growth 1Y-20.4%
FCF growth 3Y-6.75%
FCF growth 5Y6.9%
OCF growth 1Y-18.24%
OCF growth 3Y-6.19%
OCF growth 5Y7.14%
ABBVIE INC / 4AB.DE FAQ
What is the ChartMill fundamental rating of ABBVIE INC (4AB.DE) stock?
ChartMill assigns a fundamental rating of 5 / 10 to 4AB.DE.
What is the valuation status of ABBVIE INC (4AB.DE) stock?
ChartMill assigns a valuation rating of 5 / 10 to ABBVIE INC (4AB.DE). This can be considered as Fairly Valued.
How profitable is ABBVIE INC (4AB.DE) stock?
ABBVIE INC (4AB.DE) has a profitability rating of 6 / 10.
What are the PE and PB ratios of ABBVIE INC (4AB.DE) stock?
The Price/Earnings (PE) ratio for ABBVIE INC (4AB.DE) is 23.62 and the Price/Book (PB) ratio is -149.31.
Can you provide the expected EPS growth for 4AB stock?
The Earnings per Share (EPS) of ABBVIE INC (4AB.DE) is expected to grow by 7.28% in the next year.